Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2006-09-05
2006-09-05
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C544S235000, C548S183000, C546S158000, C514S314000, C514S326000, C514S369000, C514S389000
Reexamination Certificate
active
07102000
ABSTRACT:
The present invention relates to certain substituted heterocycles of Formula (200),wherein B, H, I, J and K together with the Ar5form a ring containing at least one amide residue, and W, X, Y and Z together form a 2,4-thiazolidinedione, 2-thioxo-thiazolidine-4-one, 2,4-imidazolidinedione or 2-thioxo-imidazolidine-4-one residue; or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of diseases such as type 2 diabetes, and related disorders of lipid and carbohydrate metabolism, including atherosclerosis. The compounds are also useful for treating diseases of uncontrolled proliferation, such as cancers in general, including breast cancer.
REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kühl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4824833 (1989-04-01), Iijima et al.
patent: 4897393 (1990-01-01), Iijima et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5599826 (1997-02-01), Mertens et al.
patent: 5650444 (1997-07-01), Cagiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 5811439 (1998-09-01), Ogawa et al.
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6262044 (2001-07-01), Møller et al.
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 2002/0143182 (2002-10-01), Pfahl et al.
patent: 2003/0083357 (2003-05-01), Pfahl et al.
patent: 2003/0105333 (2003-06-01), Pfahl et al.
patent: 2003/0144329 (2003-07-01), Pfahl et al.
patent: 2003/0153606 (2003-08-01), Pfahl et al.
patent: 2003/0216432 (2003-11-01), Pfahl et al.
patent: 2004/0034004 (2004-02-01), Pfahl et al.
patent: 2004/0097566 (2004-05-01), Pfahl et al.
patent: 2005/0014767 (2005-01-01), Pfahl et al.
patent: 2005/0038098 (2005-02-01), Tachdijan et al.
patent: 2005/0070581 (2005-03-01), Pfahl et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 343 643 (1989-11-01), None
patent: 1 048 659 (2000-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/24415 (1999-05-01), None
patent: WO 99/58127 (1999-11-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 00/066167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 02/072009 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
patent: WO 02/080935 (2002-10-01), None
Bozdag, CA 133:309865, abstract of Arzneimittel-Forschung, 2000, vol. 50(7), pp. 626-630.
Bozdag, CA 133:237715, Arzneimittel-Forschung, 2000, vol. 50(6), pp. 539-543.□□.
Ertan, CA 126:293290, Acta pharmaceutica Turcica, 19997, vol. 39(1), pp. 33-37.
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,”Cancer Re., 48:589-601 (1988).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,”Nitric pin. Rheumatol, 11(3):202-209 (1999).
Aranyos et al., “Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,”J. Am. Chem. Soc., 121:4369-4378 (1999).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children,”Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstein Registry No. 52, 1978, Compound Registry No. 4939128.
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis, 829-830 (1981).
Blondet et al., “Convenient Synthesis of 6-Methyl, 8-Methyl and 6,8-Dimethyl Derivatives of 5-Hydroxy-1,2,3,4-Tetrahydro-2-Quinolinone,”Organic Preparation and Procedures Int., 25(2):223-228 (1993).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,”J. Org. Chem., 15(2) 374-376 (1950).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci., 87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNF Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis,”Lancet, 2:244-247 (1989).
Cantello et al., “A Versatile Route to 2-Arylmethyl-1,2-oxadiazolidine-3,5-dionesviaRegiospecific Alkyl-ation of 1,2,4-Oxadiazolidine-3,5-dione,”Synlett, 263-264 (1997).
Cantello et al., “The Synthesis of BRL 49653—A Novel and Potent Antihyperglycaemic Agent,”Bioorganic&MedicinalChemistry Letters, 4:1181-1184 (1994).
Chan et al., “New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate,”Tetrahedron Letters, 39:2933-2936 (1998).
Chang et al., “The Upjohn Colony of KkayMice: A Model for Obese Type II Diabetes,”Elsevier Science Publishers B.V., Biomedical Division, Diabetespp. 466-470 (1986).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activities of Ligands Binding Retinoic Acid Receptor Subtypes,”J. Med. Chem., 38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention,”Gut, 35:950-954 (1994).
Cobb et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem., 41:5055-5069 (1998).
Coleman “Diabetes-Obesity Syndromes in Mice,”Diabetes, 31(1):1-6 (Apr. 1982).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryl- and Alkenylboronic Acids,”Bull. Soc. Chem. Fr., 133:1095-1102 (1996).
Dawson et al., “Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity,”J. Med. Chemistry, 38:3368-3383 (1995).
Dawson et al., “The Synthetic Chemistry of Retinoids,”Biology, Chemistry, and Medicine, 2ndEdition, Raven Press, Ltd., New York (1994).
Ebisawa et al., “Novel Thiazolidinedione Derivatives with Retinoid Synergistic Activity,”Biol. Pharma. Bull., 21(5):547-549 (1998).
Evans et al., “Synthesis of Diaryl Ethers through the Copper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine,”Tetrahedron Letters, 39:2937-2940 (1998).
Farahat et al., “Cytokine Epression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis,”Ann. Rheum. Dis., 52: 870-875 (1993).
Ferrell, “Tripping the Switch Fantastic: How A Protein Kinase Cascade Can Convert Graded Inputs into Switch-Like Outputs,”TIBS, 21:460-466 (1966).
Firooznia et al., “Enantioselective Synthesis of 4-Substituted Phenylalanines By Cross-Coupling Reactions,”Tetrahedron Letters, 40:213-216 (1999).
Förstermann et al., “Induced RAW 264.7 Macrophages Express Soluble and Particulate Nitric Oxide Synthase: Inhibition By Transfo
Al-Shamma Hussien A.
Boudjelal Mohamed
Giachino Andrea Fanjul
Guo Jianhua
Jakubowicz-Jaillardon Karine
Incyte San Diego Inc.
Needle & Rosenberg P.C.
Ortho -McNeil Pharmaceutical, Inc.
Seaman D. Margaret
LandOfFree
Heterocyclic amide derivatives for the treatment of diabetes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic amide derivatives for the treatment of diabetes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic amide derivatives for the treatment of diabetes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544661